Page 21 - CASA Bulletin of Anesthesiology 2022; 9(5)
P. 21

Vol. 9, No 5, 2022


                 The Role of Dexmedetomidine on Immunoregulation in Perioperative
                                                   Pain Management


                                           Isabelle Yang MD, Jingping Wang MD, Ph.D.

                          Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General
                                             Hospital, Harvard Medical School.


               Introduction

                   With growing concerns related to the opioid crisis, multimodal analgesia has been employed
               increasingly in clinical settings over the last two decades.  Multimodal analgesia is a strategy to
                                                                       1, 2
               use multiple drugs that act by different mechanisms along multiple sites of the nociceptive
               pathway.  Effective perioperative analgesia can be achieved via opioid-sparing or even opioid-
                        3, 4
               free analgesia, though it may not always clinically necessary or appropriate.
                                                                                        5, 6
                   Common perioperative analgesic agents include opioids as well as non-opioid systemic
               analgesics such as dexmedetomidine, ketamine, acetaminophen, non-steroidal anti-inflammatory
               drugs, gabapentinoids, regional anesthesia, and local anesthetics administered intravenously or
               by infiltration.

                   Among the potential perioperative analgesics, dexmedetomidine (DEX) has emerged as a
               common alternative or adjunct to opioids. One unique advantage of DEX over opioids is its
               beneficial effects on the immune system. Whereas the studied effects of opioids, primarily
               morphine, have been shown to exhibit predominantly immunosuppressive effects, DEX has been
               shown to have reduced immunosuppressive effects and even beneficial immunomodulatory
               effects in pre-clinical studies.  These observations raised the possibility that DEX is a superior
                                            7
               alternative to opioids in cases where intact immune response to surgical and other stressors is
               beneficial such as cancer and sepsis.
                                                  8
                   Several pre-clinical studies have been performed on the effects of DEX on innate immune
               function. DEX exerts effects on the immune system via several pathways, including directly via
               alpha-2 adrenergic receptors which are found on many immune cells, indirectly through its
               sympatholytic effects on the central and peripheral nervous system and the associated changes
               with increased catecholamines, and indirectly through other cell signaling mechanisms.  In
                                                                                                   8
               general, DEX is thought to preserve innate immunity through preserved natural killer cell
               function, neutrophil function (chemotaxis, phagocytosis, and production of superoxide radicals),
               and intact macrophage activation and function but decreased secretion of inflammatory
               cytokines.  However, more research is needed to test these observations in clinical studies.
                         9
               Immune markers
                   A meta-analysis conducted by Wang et al in 2019 reviewed sixty-seven studies (including
               fifty-nine randomized controlled trials (RCTs) and eight cohort studies) with 4842 patients
               assessed, of which 2454 patients were in DEX groups and 2388 patients were in control (without
               DEX) groups. Cardiac, abdominal, thoracic, spine, orthopedic, genitourinary, and other cancer
               surgeries comparing DEX to placebo, propofol, morphine, hydromorphone, fentanyl, and
                                                                                            P a g e  20 | 66
   16   17   18   19   20   21   22   23   24   25   26